Tigermed Calls March 2026 EGM to Approve Registered Address Change

Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has issued an update.

Hangzhou Tigermed Consulting has called its first extraordinary general meeting of 2026 for March 5 in Hangzhou to seek shareholder approval for a change of its registered address and related amendments to its articles of association. Holders of both A shares and H shares will vote together by poll, with specific registration, proxy, and attendance procedures laid out, underscoring corporate governance formalities that may precede an operational or administrative relocation for the company.

The meeting requires a two-thirds majority of voting rights represented in person or by proxy to pass the special resolution, and the company has set a share register closure period in early March to determine eligible H-share voters. While framed as a technical change, the proposed address shift and constitutional amendments may signal organizational adjustments within Tigermed’s structure, with implications for how it manages its legal domicile and regulatory compliance going forward.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$61.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

More about Hangzhou Tigermed Consulting Co., Ltd. Class H

Hangzhou Tigermed Consulting Co., Ltd. is a China-based company listed in Hong Kong that operates in the pharmaceutical and clinical research services industry. The group provides contract research and related consulting services to drug developers, leveraging its presence in the domestic Chinese market and broader international capital markets through its H-share listing.

YTD Price Performance: 26.94%

Average Trading Volume: 2,227,590

Technical Sentiment Signal: Buy

Current Market Cap: HK$57.51B

For a thorough assessment of 3347 stock, go to TipRanks’ Stock Analysis page.